Drug Trial Radar · NCT07093697
A Study to Evaluate the Efficacy and Safety of DW5121 Compared to DW51211 and DW51212
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
273
Actual
Start
Mar 28, 2024
Primary completion
May 27, 2025
Study completion May 27, 2025
Sponsor
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-blind, active-controlled, parallel-group, multi-center clinical trial to evaluate the efficacy and safety of DW5121 compared to DW51211 and DW51212 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of DW5121 over DW51211 and DW51212 by comparing the change in total Bronchitis Severity Score (BSS) at Day 4 after administration. Approximately equal numbers of patients were randomized in a 1:1:1 ratio to receive DW5121, DW51211, or DW51212 for 7 days. Efficacy and safety assessments were conducted at Day 4 and Day 7, with a follow-up contact approximately 5 days after the end of treatment to monitor adverse events.
Conditions
- Acute Bronchitis
Interventions
DW5121Drug
Participants receive DW5121, 2 tablets orally, DW51211 Placebo, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days
DW51211Drug
Participants receive DW5121 placebo, 2 tablets orally, DW51211, 2 tablets orally, DW51212 Placebo, 1 tablets orally, 3 times a day after meals for 7 days
DW51212Drug
Participants receive DW5121 placebo, 2 tablets orally, DW51211 placebo, 2 tablets orally, DW51212 , 1 tablets orally, 3 times a day after meals for 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Bronchitis Severity Score (BSS) total score at Day 4 after dosingTime frame: Day 4 after first dose
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Soonchunhyang University Bucheon Hospital
Bucheon-si, South Korea
Hallym University Chuncheon Sacred Heart Hospital
Chuncheon, South Korea
Yeungnam University Medical Center
Daegu, South Korea
Wonkwang University Hospital
Iksan, South Korea
Kangbuk Samsung Hospital
Seoul, South Korea
Konkuk University Medical Center
Seoul, South Korea
Hallym University Kangdong Sacred Heart Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.